ceniises 1 divided by 100 is .01 which is one percent.
My reading of the results were that there were 1055 tested. 2 were inconclusive and the rest 1053 of 1053 or 100% were correct.
It wasn't that the 2 tests were "wrong" or incorrect, but that they couldn't be determined.
Lets get over the small details. Calypte has some things going for it .
1. Calypte has a rapid oral test that works.
2. It has been approved in Russia and India two large countries as well as several smaller ones
3. It has been proven effective in China and should be approved there shortly.
4. If you ask anyone whether they would rather give blood or be swabbed in the mouth, most will pick being swabbed in the mouth.
5. Oral tests are safer than blood tests as respects accidental infections especially to test givers.
6. Calypte presently has a longer shelf life than only other rapid oral test (Orasure).
7. Calypte presently ahead of Orasure in getting approvals in large markets overseas.
These are all positives of Calypte and have been highly touted by management.
However sales so far have been abysmal. Why?
1. It is still early in approval arana in large countries like Russia and India.
2. Calypte's rapid oral test is 3-10 times as expensive as rapid blood tests.
3. Rapid blood tests are the accepted standard in HIV tests.
4. Calypte tests are not FDA, EU, or WHO approved.
5. Calypte rapid tests are not approved for use in any country where they are manufactured.
6. If blood is drawn for test results other than HIV some could be used for less expensive rapid blood tests and the more expensive rapid oral tests would be unneccessary.
7. Calypte has been unable to show a profit on its sales of rapid tests in competive pricing in overseas markets.
8. The distribution system with 10 times retail markup has hurt sales in some countries (i.e UAE)
9. Compared to many of its competitors, Calypte's financial situation could best be described as "precarious".
Now you see both sides of the coin. There are some advantages and some disadvantages to Calypte.
News 
Market Data 
Discover 
AI
